Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it
Clin. transl. oncol. (Print)
; 19(6): 658-666, jun. 2017. tab
Artigo
em Inglês
| IBECS
| ID: ibc-162823
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Anaplastic lymphoma kinase (ALK) rearrangement is detected in 3-7% of patients with non-small-cell lung cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the treatment of ALK-positive lung cancer. Despite the initial enthusiasm, most of the patients develop resistance within the first year of treatment. The main mechanisms are secondary mutations and bypass track activation. Moreover, crizotinib has low penetration into the central nervous system. The need to overcome these limitations has led to the development of second-generation inhibitors that have better effectiveness against crizotinib-resistant mutations and brain metastases. Ceritinib and alectinib are the only approved drugs of this group. Many ongoing trials try to define the most appropriate agent for the treatment of ALK-positive lung cancer depending on the responsible mechanism. This review focuses on the current data regarding the potential mechanisms of resistance to ALK inhibitors and the strategies to overcome it (AU)
RESUMEN
No disponible
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Carbazóis
/
Linfoma Anaplásico de Células Grandes
/
Carcinoma Pulmonar de Células não Pequenas
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2017
Tipo de documento:
Artigo
Instituição/País de afiliação:
Sotiria General Hospital/Greece
/
St. Savvas Regional Hospital for Cancer Treatment/Greece